Korneale Zelltherapie – Eine Übersicht

Fuest, Matthias; Yam, Gary Hin‐Fai; Peh, Gary S L; Walter, Peter; Plange, Niklas

doi:10.1007/s00347-017-0454-6

Cited by 3 publications

(3 citation statements)

References 101 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 1 , 5 However, many factors restrict the long‐term success including limited graft survival, allogeneic graft rejection, the need for immunosuppressants, high associated costs and most importantly the global donor material shortage. 1 , 6 …”

Section: Introductionmentioning

confidence: 99%

“… 2 , 8 Corneal cell therapy has seen great advances, particularly for the epithelial and endothelial layers. 1 , 6 , 9 , 10 Nevertheless, the targeted delivery of cells into the cornea to treat stromal disease, which could possibly replace corneal transplantation for some indications in the future, is still in its beginnings. 1 , 4 , 11 , 12 …”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Human platelet lysate as a replacement for fetal bovine serum in human corneal stromal keratocyte and fibroblast culture

Seidelmann

Campos

Rohde

et al. 2021

J Cellular Molecular Medi

View full text Add to dashboard Cite

The isolation and propagation of primary human corneal stromal keratocytes (CSK) are crucial for cellular research and corneal tissue engineering. However, this delicate cell type easily transforms into stromal fibroblasts (SF) and scar inducing myofibroblasts (Myo‐SF). Current protocols mainly rely on xenogeneic fetal bovine serum (FBS). Human platelet lysate (hPL) could be a viable, potentially autologous, alternative. We found high cell survival with both supplements in CSK and SF. Cell numbers and Ki67+ ratios increased with higher fractions of hPL and FBS in CSK and SF. We detected a loss in CSK marker expression (Col8A2, ALDH3A1 and LUM) with increasing fractions of FBS and hPL in CSK and SF. The expression of the Myo‐SF marker SMA increased with higher amounts of FBS but decreased with incremental hPL substitution in both cell types, implying an antifibrotic effect of hPL. Immunohistochemistry confirmed the RT‐PCR findings. bFGF and HGF were only found in hPL and could be responsible for suppressing the Myo‐SF conversion. Considering all findings, we propose 0.5% hPL as a suitable substitution in CSK culture, as this xeno‐free component efficiently preserved CSK characteristics, with non‐inferiority in terms of cell viability, cell number and proliferation in comparison to the established 0.5% FBS protocol.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Human platelet lysate as a replacement for fetal bovine serum in human corneal stromal keratocyte and fibroblast culture

Seidelmann

Campos

Rohde

et al. 2021

J Cellular Molecular Medi

View full text Add to dashboard Cite

show abstract

“…The World Health Organization (WHO) reported the worldwide blind population was 39 million in 2012 14, and this problem is getting worse due to aging population and donor cornea shortage. Because corneal transplantation is the only effective treatment to cure this kind of disease (reviewed in 15), it is therefore paramount to develop HCEC grafts in vitro which may be used to transplant into people suffering from corneal blindness caused by corneal endothelial dysfunction (reviewed in 16, 17).…”

Section: Introductionmentioning

confidence: 99%

Engineering of Human Corneal Endothelial Cells In Vitro

Zhu¹,

Zhu²,

Tighe³

et al. 2019

Int. J. Med. Sci.

View full text Add to dashboard Cite

Human corneal endothelial cells are responsible for controlling corneal transparency, however they are notorious for their limited proliferative capability. Thus, damage to these cells may cause irreversible blindness. Currently, the only way to cure blindness caused by corneal endothelial dysfunction is via corneal transplantation of a cadaver donor cornea with healthy corneal endothelium. Due to severe shortage of donor corneas worldwide, it has become paramount to develop human corneal endothelial grafts in vitro that can subsequently be transplanted in humans. Recently, we have reported effective expansion of human corneal endothelial cells by reprogramming the cells into progenitor status through use of p120-Kaiso siRNA knockdown. This new reprogramming approach circumvents the need of using induced pluripotent stem cells or embryonic stem cells. Successful promotion of this technology will encourage scientists to rethink how "contact inhibition" can safely be perturbed to our benefit, i.e., effective engineering of an in vivo-like tissue while successful maintaining the normal phenotype. In this review, we present current advances in reprogramming corneal endothelial cells in vitro, detail the methods to successful engineer human corneal endothelial grafts, and discuss their future clinical applications to cure corneal blindness.

show abstract